Teva invests $1M in Israel's Cellcure Neurosci

9 September 2007

World generic giant Teva Pharmaceutical Industries is investing $1.0 million in tissue technology startup Cellcure Neurosciences, a stem cell therapy company focused on cures for Parkinson's disease and other neurodegenerative disorders, according to Israel's Haaretz.com.

The investment prices Cellcure at $13.0 million, said Israel's Hadasit Bio-Holdings, which also owns a stake in the firm. One of Teva's two innovative drugs, Azilect (rasagiline), is a treatment for PD. The agent earned $28.0 million in second-quarter 2007 (Marketletter August 20).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight